Solasia Pharma KK (TSE:4597) Research & Development: 円428.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4597 Solasia Pharma KK TSE:4597
70 GF Score
Price 円30.00
GF Value 円30.93
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Solasia Pharma KK Research & Development?

Solasia Pharma KK TSE:4597 +3.45% 70 Research & Development is 円428.0 Mil as of Jun. 2026. GuruFocus rates TSE:4597 with a GF Score™ of 70/100 and a GF Value™ of 円30.93 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Solasia Pharma KK's Research & Development for the three months ended in Jun. 2026 was 円118.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was 円428.0 Mil.

Solasia Pharma KK  (TSE:4597) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Solasia Pharma KK Research & Development Related Terms

Solasia Pharma KK Research & Development Historical Data

* Premium members only.

The historical data trend for Solasia Pharma KK's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solasia Pharma KK Research & Development Chart

Solasia Pharma KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 845.00 883.00 403.00 414.00 430.00

Solasia Pharma KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.00 82.00 116.00 112.00 118.00
TSE:4597
70GF Score
Solasia Pharma KK TSE:4597
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solasia Pharma KK Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円428.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円428.0 Mil mean?
Solasia Pharma KK (TSE:4597) has a Research & Development of 円428.0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Solasia Pharma KK and its competitors.
Is Solasia Pharma KK's Research & Development too high?
Solasia Pharma KK's current Research & Development is 円428.0 Mil. Overall, Solasia Pharma KK has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's Research & Development compare to ZTS?
Solasia Pharma KK's Research & Development of 円428.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Solasia Pharma KK and its competitors. Solasia Pharma KK's current Research & Development is 円428.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (TSE:4597) is currently considered Fairly Valued. The stock's GF Value™ is 円30.93, compared to a current price of 円30.00 — trading 3% below its estimated fair value. The current Research & Development is 円428.0 Mil. Solasia Pharma KK's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Solasia Pharma KK (TSE:4597), the current Research & Development is 円428.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solasia Pharma KK (TSE:4597) Overvalued in 2026?

Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be undervalued. The current stock price of 円30.00 is trading 3% below its estimated GF Value™ of 円30.93. GuruFocus considers Solasia Pharma KK to be Fairly Valued.

Key valuation signals for TSE:4597:

  • Research & Development: 円428.0 Mil
  • GF Value™: 円30.93 vs. price of 円30.00 (3% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the TSE:4597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Solasia Pharma KK Business Description

Other Exchanges 9SO:Germany
Address 2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.
70GF Score

Get the complete analysis for TSE:4597

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円30.00
Price
円30.93
GF Value